Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| benzoporphyrin derivatives | 5273 | 759457-82-4 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Padeliporfin is retained within the vascular system. When activated with 753 nm wavelength laser light, padeliporfin triggers a cascade of pathophysiological events resulting in focal necrosis within a few days. Activation within the illuminated tumour vasculature, generates oxygen radicals causing local hypoxia that induces the release of nitric oxide radicals. This results in transient arterial vasodilatation that triggers the release of the vasoconstrictor, endothelin-1. Rapid consumption of the NO radicals, by oxygen radicals, leads to the formation of reactive nitrogen species (RNS) (e.g. peroxynitrite), in parallel to arterial constriction. In addition, impaired deformability is thought to enhance erythrocyte aggregability and formation of blood clots at the interface of the arterial supply (feeding arteries) and tumour microcirculation, results in occlusion of the tumour vasculature. This is enhanced by RNS-induced endothelial cell apoptosis and initiation of self-propagated tumour cells necrosis through peroxidation of their membrane.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 10, 2017 | EMA | STEBA Biotech S.A |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L01XD07 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Sensitizers used in photodynamic/radiation therapy |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Adenocarcinoma of prostate | indication | 399490008 | DOID:2526 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| EEO29FZT86 | UNII |
| 698393-30-5 | SECONDARY_CAS_RN |
| C2698706 | UMLSCUI |
| CHEBI:757787 | CHEBI |
| CHEMBL4594284 | ChEMBL_ID |
| 171041442 | PUBCHEM_CID |
| DB15575 | DRUGBANK_ID |
| CHEMBL4594285 | ChEMBL_ID |
| D10973 | KEGG_DRUG |
| 8679 | INN_ID |
| C503696 | MESH_SUPPLEMENTAL_RECORD_UI |
| C456120 | MESH_SUPPLEMENTAL_RECORD_UI |
None